Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Said Q4 Revenues Sank 60 Percent as Net Losses Swelled 20 Percent

NEW YORK, Feb. 8 (GenomeWeb News) - Compugen today reported a 60-percent decline in fourth-quarter revenues and a 20-percent jump in net losses.


The Israel-biotech company said revenues for the three months ended Dec. 31, 2004, sank to $552,000 from $1.4 million in revenues for the same period in 2003.


Compugen attributed its slide for both the fourth quarter and fiscal year 2004 to the discontinuation of certain products tied to the company's new focus on diagnostics and drug discovery.


R&D spending in the quarter inched up to $3.5 million from $3.3 million year over year.


Compugen said fourth-quarter net losses widened to $3.7 million from $3.5 million in the year-ago period.


As of Dec. 31, 2004, Compugen had $48.4 million in cash, cash equivalents, and marketable securities.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.